Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Gains from Investment Securities (2019 - 2024)

Capricor Therapeutics (CAPR) has 9 years of Gains from Investment Securities data on record, last reported at $458869.0 in Q3 2024.

  • For Q3 2024, Gains from Investment Securities fell 63.71% year-over-year to $458869.0; the TTM value through Sep 2024 reached $458869.0, down 63.71%, while the annual FY2024 figure was $2.0 million, 76.03% down from the prior year.
  • Gains from Investment Securities reached $458869.0 in Q3 2024 per CAPR's latest filing, up from $377866.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.2 million in Q4 2023 and bottomed at $377866.0 in Q1 2024.
  • Average Gains from Investment Securities over 4 years is $2.7 million, with a median of $1.9 million recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: decreased 14.07% in 2023, then crashed 78.49% in 2024.
  • A 4-year view of Gains from Investment Securities shows it stood at $2.3 million in 2020, then grew by 14.16% to $2.6 million in 2022, then soared by 211.57% to $8.2 million in 2023, then plummeted by 94.43% to $458869.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $458869.0 in Q3 2024, $377866.0 in Q1 2024, and $8.2 million in Q4 2023.